Illumina扩大HiSeq X测序系统的使用 用于非人类物种

  近日，Illumina公司宣布，他们将扩大HiSeq X测序系统的使用来促进用户对非人类的物种进行全基因组测序，这项更新后的使用权利或将使得HiSeq X和HiSeq X Five用户的权利立马生效，同时也将为所有的新客户提供测序系统的服务。
  在世界上第一个1000美元的人类基因组及人口规模测序强烈需求的驱动下，自从2014年1月起就有超过12.5万人类全基因组样本已经相继在该测序平台中进行了测序；这项使用权利的更新将会在多个市场扩大对非人类物种的人口规模尺度的测序，其中就包括农业研究中的植物类和家畜类，以及制药工业研究中的模式有机体；此前对非人类物种进行高覆盖率的测序往往代价较高。
  Illumina公司科技运营总监Emma Mill表示，维尔康姆基金会桑格研究院（Wellcome Trust Sanger Institute）非常高兴可以利用HiSeq X平台来对非人类的物种的基因组进行测序，而理解非人类物种的遗传和生物学过程也是桑格研究院的研究重点之一，而更新后的权利将可帮助开展大规模的全基因组测序项目；目前桑格研究院计划将全基因组的人口测序扩大至多个医学相关的有机体。
  Illumina总裁Francis deSouza表示，用于人口规模研究的HiSeq X系统的市场普及已经超出了我们的预期，我们也期待新的客户来将他们的研究推向一个新的高度，在每个基因组超高通量及空前价格的条件下，相信HiSeq X系统将为用户们提供一种重塑超出人类的全基因组测序及经济的机会。
  关于Illumina公司
  Illumina公司致力于利用基因组的力量来改善人类健康，公司的创新性关注已经使其成为了DNA测序和阵列技术的全球领导者，目前Illumina公司为研究机构、临床以及应用市场的客户提供服务，公司的产品主要用于生命科学研究、肿瘤学、生殖健康、农业及其它相关领域。
  前瞻性声明
  这项风险中涉及一定风险和不确定性，导致实际结果不同于任何前瞻性声明的重要因素已经在证券交易委员会的相关文件中清晰地进行了描述，其中就包括最近递交的10-K和10-Q，或者在公共会议上披露的信息；在本公告发布的日期后我们并不打算更新任何前瞻性的声明。（转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的原文摘要：

Illumina Expands Use of HiSeq X™ Sequencing System to Include Non-Human Species
Illumina, Inc.  (NASDAQ:ILMN) today announced it has expanded the rights of use for the HiSeq X Sequencing System to allow customers to perform whole-genome sequencing of non-human species. The updated rights of use will take effect immediately for existing customers of the HiSeq X Ten and HiSeq X Five, and will apply to all new customers of the sequencing systems.

Driven by the world's first $1,000 human genome and significant demand for population-scale sequencing, more than 125,000 human whole-genome samples have been sequenced on the platform since its release in January 2014 . The updated rights of use will allow for market expansion and population-scale sequencing of non-human species in a variety of markets, including plants and livestock in agricultural research and model organisms in pharmaceutical research. Previously, it has been cost prohibitive to sequence non-human genomes at high coverage.

"The Wellcome Trust Sanger Institute is excited to be able to sequence non-human genomes on the HiSeq X Platform," said Emma Millican, Director of Scientific Operations. "Understanding the genetics and biological processes of non-human organisms is a major area of focus for the Sanger Institute and this update will enable large-scale whole-genome sequencing projects, important for public health, that otherwise would not have happened. The Sanger Institute plans to extend whole-genome population sequencing to many more medically relevant organisms in the future."

"Market adoption of the HiSeq X system for population-scale studies has exceeded our expectations and we are excited for new and existing customers to take their research to new heights," said Francis deSouza, President of Illumina . "With its ultrahigh throughput and unprecedented price point per genome, the HiSeq X system now provides customers with an opportunity to reshape the economics and scale of whole-genome sequencing beyond the human species."

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission , including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.